Quo vadis antiviral agents for herpes, influenza and HIV?

References

1. Field H. J. Famciclovir/penciclovir: Pharmacology and Pharmacokinetics Workshop. Proceedings of a meeting held at Cliveden, Maidenhead, UK, on 23 April 1993. Antiviral (Them Chemother) 1993; 4: (Suppl. 1)
   [Google Scholar]
2. Field H. J., Griffiths P. D., Oxford J. S. Evaluating new antiviral drugs. Proceedings of a meeting held in Switzerland, 17–20 December, 1993. AntiviralChem Chemother 1994; 5: (Suppl. 1)
   [Google Scholar]
3. Tilson B. B., Eagle C. R., Andrews E. B. Safety of acyclovir: a summarv of the first 10 years experience. J Med Virol 1993 (Suppl. 1) 67–73
   [Google Scholar]
4. Collins P., Ellis M. N. Sensitivity monitoring of clinical isolates of herpes simplex virus to acyclovir. J Med Virol 1992 (Suppl. 1) 58–66
   [Google Scholar]
5. Safrin S., Crumpacker C., Chatis P. A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. N Eng J Med 1991; 325:551–555
   [Google Scholar]
6. Boyd M. R., Safrin S., Kera E. R. Penciclovir: a review of its spectrum of activity, selectivity, and cross-resistance pattern. Antiviral Chem Chemother 1993; 4: (Suppl. 1) 3–11
   [Google Scholar]
7. Hamden M. R., Jarvest R. L. An improved synthesis of the antiviral acyclonucleoside 9-(4-hydroxy-3-hydroxymethylbut-l-yl) guanine. Tetrahedron Lett 1985; 26:4265–4268
   [Google Scholar]
8. Vere-Hodge R. A., Sutton D., Boyd M. R., Hamden M. R., Jarvest R. L. Selection of an oral pro-drug (BRL 42810 Famciclovir) for the antiherpes virus agent BRL 39123 [9-(4-hydroxy-3-hydroxymethylbut-l-yl) guanine; penciclovir. Antimicrob Agents Chemother 1989; 33:1765–1773
   [Google Scholar]
9. Weller S., Blum M. R., Doucette M. Pharmacokinetics of the acyclovir pro-drug, valaciclovir, after escalating single- and multiple-dose administration to normal volunteers. Clin Pharmaco Therapeut 1993; 54:595–605
   [Google Scholar]
10. Ho D. D., Neumann A. V., Perelson A. S., Chen W., Leonard J. M., Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995; 373:123–126
    [Google Scholar]
11. Wain-Hobson S. Virological mayhem. Nature 1995; 373:102
    [Google Scholar]
12. Stein C. A., Levantis P., Goh B., Hillman R., Oxford J. S. Limiting dilution PCR to detect changes in the RT of patients on long term AZT treatment. Tenth International Congress on AIDS Yokohama, Japan: 1994
    [Google Scholar]
13. Stein C. A., Levantis P., Oxford J. S. Sequence analysis of proviral HIV RT amplified directly by a semi-quantitative technique from AZT treated patients. J Med Virol 1994; 44:115–121
    [Google Scholar]
14. Oxford J. S. Chemotherapy of influenza and respiratory viruses. In Dimmock N. J., Griffiths P. D., Madeley C. R. (eds) Control of virus diseases Society for General Microbiology, Symposium no. 45 Cambridge: Cambridge University Press; 1990 pp 213–242
    [Google Scholar]
15. Oxford J. S., Logan I. S., Potter C. W. In vivo selection of an influenza A2 strain resistant to amantadine. Nature 1970; 226:82–83
    [Google Scholar]
16. Hayden F. G., Hay A. J. Emergence and transmission of influenza A viruses resistant to amantadine and rimantadine. Curr Topics Microbiol Immunol 1992; 176:119–130
    [Google Scholar]
17. Heider H., Adamczyk B., Presber H. W., Schroeder C., Feldblum R., Indulen M. K. Occurrence of amantadine- and rimantadine-resistant influenza A strains during the 1980 epidemic. Acta Virologica 1981; 25:395–400
    [Google Scholar]
18. Palese P., Schulman J. L. Inhibitors of viral neuraminidase as potential antiviral drugs. In Oxford J. S. (ed) Chemoprophylaxis and virus infections of the respiratory tract vol 1 Cleveland: CH, CRC Press; 1977
    [Google Scholar]
19. Von Itzstein M., Wu W.-Y., Kotz G. B. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 1993; 363:418–423
    [Google Scholar]
20. Hayden F. G., Lobo M., Esinhart J., Hussey E. 34th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1994
21. Habeshaw J. W. HLA mimicry by HIV-1 gp120 in the pathogenesis of AIDS. Immunol Today 1994; 15:39–40
    [Google Scholar]
22. Wilson S. E., Hounsell E., Habeshaw J. A. Generation of auto and alio cytotoxic T cell responses by regions of HIV gp120 which share structural homology with human MHC class I/II molecules. IXth International Conference on AIDS; Berlin: 1993
    [Google Scholar]